| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of acute pulmonary embolism with severe haemoptysis
|
Le Mao, Raphael
|
|
|
208 |
C |
p. 199-201
|
artikel
|
| 2 |
Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes
|
Ballerie, Alice
|
|
|
208 |
C |
p. 39-44
|
artikel
|
| 3 |
A survey of current anticoagulation patient education practices and development
|
Jones, Aubrey E.
|
|
|
208 |
C |
p. 11-13
|
artikel
|
| 4 |
Clinical course, management, and platelet activity assessment of splanchnic VITT: A case report
|
Corica, Bernadette
|
|
|
208 |
C |
p. 14-17
|
artikel
|
| 5 |
Clinical outcomes of dabigatran use in patients with non-valvular atrial fibrillation and weight >120 kg
|
Coates, Jamie
|
|
|
208 |
C |
p. 176-180
|
artikel
|
| 6 |
Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: A systematic review and meta-analysis
|
Swayngim, Rebecca
|
|
|
208 |
C |
p. 18-25
|
artikel
|
| 7 |
Corrigendum to “Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism” [Thromb. Res. 193 (2020) 160–165]
|
Trujillo-Santos, Javier
|
|
|
208 |
C |
p. 233
|
artikel
|
| 8 |
COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets
|
Pitkänen, Hanna H.
|
|
|
208 |
C |
p. 129-137
|
artikel
|
| 9 |
Development and validation of a predictive score for venous thromboembolism in newly diagnosed non-small cell lung cancer
|
Li, Jie
|
|
|
208 |
C |
p. 45-51
|
artikel
|
| 10 |
Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors
|
Lee, Angela
|
|
|
208 |
C |
p. 148-155
|
artikel
|
| 11 |
DOAC drug levels: Does “knowing” lead to safer care?
|
Hanigan, Sarah
|
|
|
208 |
C |
p. 127-128
|
artikel
|
| 12 |
Editorial Board
|
|
|
|
208 |
C |
p. IFC
|
artikel
|
| 13 |
Efficacy and safety of primary thromboprophylaxis for the prevention of venous thromboembolism in patients with cancer and a central venous catheter: A systematic review and meta-analysis
|
Li, Allen
|
|
|
208 |
C |
p. 58-65
|
artikel
|
| 14 |
Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial
|
Nayak, Ameeta L.
|
|
|
208 |
C |
p. 79-82
|
artikel
|
| 15 |
Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism
|
Hansen, Ellen-Sofie
|
|
|
208 |
C |
p. 121-126
|
artikel
|
| 16 |
Every 6 seconds in Europe
|
Blondon, Marc
|
|
|
208 |
C |
p. 211-212
|
artikel
|
| 17 |
External validation of a model to predict women most at risk of postpartum venous thromboembolism: Maternity clot risk
|
Ban, Lu
|
|
|
208 |
C |
p. 202-210
|
artikel
|
| 18 |
High-dose versus low-dose 4-factor prothrombin complex concentrate for factor Xa inhibitor reversal in intracranial hemorrhage
|
Davis, Spencer D.
|
|
|
208 |
C |
p. 112-116
|
artikel
|
| 19 |
Letter to the editors-in-chief reply to: Solinas et al. Venous and arterial thromboembolic events with immune check point inhibitors: A systematic review
|
Frere, Corinne
|
|
|
208 |
C |
p. 214-216
|
artikel
|
| 20 |
Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study
|
Bartoli-Abdou, John K.
|
|
|
208 |
C |
p. 162-169
|
artikel
|
| 21 |
Long-term VTE treatment with rivaroxaban: Results from the DRESDEN NOAC REGISTRY
|
Marten, Sandra
|
|
|
208 |
C |
p. 181-189
|
artikel
|
| 22 |
Lupus anticoagulant is an independent risk factor for non-thrombotic in-hospital mortality in COVID-19 patients
|
Constans, Mireia
|
|
|
208 |
C |
p. 99-105
|
artikel
|
| 23 |
Management of acute venous thromboembolism in patients taking antiplatelet therapy
|
Giraud, Marie
|
|
|
208 |
C |
p. 156-161
|
artikel
|
| 24 |
Massive intrasplenic arterial thrombosis in a patient with chronic ITP during the development of an Evans syndrome
|
Diez-Feijóo, R.
|
|
|
208 |
C |
p. 226-229
|
artikel
|
| 25 |
Novel prenatal diagnosis of protein C deficiency and primary prophylaxis with protein C concentrate
|
Prosser, Alexandra
|
|
|
208 |
C |
p. 145-147
|
artikel
|
| 26 |
Outcomes of isolated distal thrombosis managed with serial compression ultrasonography
|
Brewster, Alexandra C.
|
|
|
208 |
C |
p. 66-70
|
artikel
|
| 27 |
Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study
|
van Haaps, Thijs F.
|
|
|
208 |
C |
p. 35-38
|
artikel
|
| 28 |
Publisher note
|
|
|
|
208 |
C |
p. 173-175
|
artikel
|
| 29 |
Reasons for non-adherence to thromboprophylaxis prescribing guidelines in atrial fibrillation in Western Australia: A qualitative descriptive study of general practitioners' views
|
Gebreyohannes, Eyob Alemayehu
|
|
|
208 |
C |
p. 83-91
|
artikel
|
| 30 |
Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?
|
Zuin, Marco
|
|
|
208 |
C |
p. 170-172
|
artikel
|
| 31 |
Reply to the letter to the editor ‘Reply to Solinas et al, venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review’ by Frere et al.
|
Petrelli, Fausto
|
|
|
208 |
C |
p. 217-218
|
artikel
|
| 32 |
Report on effective treatment and genetic predisposition in two children with refractory probable catastrophic antiphospholipid syndrome
|
Pongphitcha, Pongpak
|
|
|
208 |
C |
p. 117-120
|
artikel
|
| 33 |
Reversal of cardiopulmonary exercise intolerance in patients with post-thrombotic obstruction of the inferior vena cava
|
Sebastian, Tim
|
|
|
208 |
C |
p. 219-225
|
artikel
|
| 34 |
Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding
|
Verso, Melina
|
|
|
208 |
C |
p. 138-144
|
artikel
|
| 35 |
Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts
|
Douillet, Delphine
|
|
|
208 |
C |
p. 4-10
|
artikel
|
| 36 |
Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis
|
Bolzacchini, Elena
|
|
|
208 |
C |
p. 190-197
|
artikel
|
| 37 |
Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy
|
Sundaravadivel, Pandarisamy
|
|
|
208 |
C |
p. 92-98
|
artikel
|
| 38 |
Special series on challenging anticoagulation cases: Experience counts when guidelines fall short
|
Bates, Shannon M.
|
|
|
208 |
C |
p. 198
|
artikel
|
| 39 |
The dynamics of thrombin formation in patients with pulmonary arterial hypertension
|
Melnichnikova, O.
|
|
|
208 |
C |
p. 230-232
|
artikel
|
| 40 |
Therapeutic anticoagulation in COVID-19 patients
|
Belfaqeeh, O.
|
|
|
208 |
C |
p. 213
|
artikel
|
| 41 |
Thrombolytic and anticoagulant effects of a recombinant staphylokinase-hirudin fusion protein
|
Ren, Keyun
|
|
|
208 |
C |
p. 26-34
|
artikel
|
| 42 |
Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study
|
Rodríguez, Carmen
|
|
|
208 |
C |
p. 1-3
|
artikel
|
| 43 |
Validation of risk assessment models for venous thromboembolism and bleeding in critically ill adolescents
|
Gupta, Anjali
|
|
|
208 |
C |
p. 106-111
|
artikel
|
| 44 |
Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy
|
Hill, Hailey
|
|
|
208 |
C |
p. 71-78
|
artikel
|
| 45 |
Venous thromboembolism risk stratification in trauma using the Caprini risk assessment model
|
Hazeltine, Max D.
|
|
|
208 |
C |
p. 52-57
|
artikel
|
Tijdschrift beschrijving